PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April

PDS Biotechnology Corporation (NASDAQ:PDSB) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totaling 1,717,509 shares, a decrease of 16.3% from the March 31st total of 2,050,834 shares. Based on an average trading volume of 1,466,066 shares, the days-to-cover ratio is presently 1.2 days. Currently, 3.4% of the company’s stock are sold short.

PDS Biotechnology Stock Up 0.8%

NASDAQ PDSB opened at $0.98 on Friday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 2.98 and a current ratio of 2.98. The firm has a 50-day simple moving average of $0.81 and a 200 day simple moving average of $0.85. PDS Biotechnology has a twelve month low of $0.51 and a twelve month high of $1.92. The stock has a market cap of $53.35 million, a PE ratio of -1.31 and a beta of 1.50.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.06. On average, research analysts forecast that PDS Biotechnology will post -0.59 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of PDSB. Marshall Wace LLP bought a new position in shares of PDS Biotechnology in the second quarter valued at approximately $91,000. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $92,000. Squarepoint Ops LLC increased its holdings in shares of PDS Biotechnology by 116.1% in the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after purchasing an additional 156,662 shares in the last quarter. Susquehanna International Group LLP increased its holdings in shares of PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock valued at $95,000 after purchasing an additional 80,937 shares in the last quarter. Finally, Tempus Wealth Planning LLC increased its holdings in shares of PDS Biotechnology by 29.3% in the fourth quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock valued at $48,000 after purchasing an additional 14,000 shares in the last quarter. Institutional investors own 26.84% of the company’s stock.

Wall Street Analyst Weigh In

PDSB has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and set a $15.00 target price on shares of PDS Biotechnology in a research report on Wednesday, April 15th. Wall Street Zen raised shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $9.00.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.